Page 73 - Read Online

Page 16 of 16 Bookland et al. J Cancer Metastasis Treat 2019;5:33 I http://dx.doi.org/10.20517/2394-4722.2018.110

75. Rani S, Gately K, Crown J, O'Byrne K, O'Driscoll L. Global analysis of serum microRNAs as potential biomarkers for lung
adenocarcinoma. Cancer Biol Ther 2013;14:1104-12.
76. Sierzega M, Kaczor M, Kolodziejczyk P, Kulig J, Sanak M, et al. Evaluation of serum microRNA biomarkers for gastric cancer based on
blood and tissue pools profiling: the importance of miR-21 and miR-331. Br J Cancer 2017;117:266-73.
77. Wang W, Li W, Ding M, Yuan H, Yang J, et al. Identification of miRNAs as non-invasive biomarkers for early diagnosis of lung cancers.
Tumour Biol 2016; doi: 10.1007/s13277-016-5442-y.
78. Wen Y, Han J, Chen J, Dong J, Xia Y, et al. Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma. Int J Cancer
2015;137:1679-90.
79. Wu Q, Lu Z, Li H, Lu J, Guo L, et al. Next-generation sequencing of microRNAs for breast cancer detection. J Biomed Biotechnol
2011;2011:597145.
80. Ferretti E, De Smaele E, Miele E, Laneve P, Po A, et al. Concerted microRNA control of Hedgehog signalling in cerebellar neuronal
progenitor and tumour cells. EMBO J 2008;27:2616-27.
81. Regazzo G, Terrenato I, Spagnuolo M, Carosi M, Cognetti G, et al. A restricted signature of serum miRNAs distinguishes glioblastoma
from lower grade gliomas. J Exp Clin Cancer Res 2016;35:124.
82. Goto G, Hori Y, Ishikawa M, Tanaka S, Sakamoto A. Changes in the gene expression levels of microRNAs in the rat hippocampus by
sevoflurane and propofol anesthesia. Mol Med Rep 2014;9:1715-22.
83. Rangaswami H, Bulbule A, Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 2006;16:79-87.
84. Kao CL, Chiou SH, Ho DM, Chen YJ, Liu RS, et al. Elevation of plasma and cerebrospinal fluid osteopontin levels in patients with
atypical teratoid/rhabdoid tumor. Am J Clin Pathol 2005;123:297-304.
85. Bacolod MD, Johnson SP, Ali-Osman F, Modrich P, Bullock NS, et al. Mechanisms of resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea
in human medulloblastoma and rhabdomyosarcoma. Mol Cancer Ther 2002;1:727-36.
86. Bacolod MD, Fehdrau R, Johnson SP, Bullock NS, Bigner DD, et al. BCNU-sequestration by metallothioneins may contribute to
resistance in a medulloblastoma cell line. Cancer Chemother Pharmacol 2009;63:753-8.
87. Krizkova S, Fabrik I, Adam V, Kukacka J, Prusa R, et al. Utilizing of adsorptive transfer stripping technique brdicka reaction for
determination of metallothioneins level in melanoma cells, blood serum and tissues. Sensors (Basel) 2008;8:3106-22.
88. Krizkova S, Masarik M, Majzlik P, Kukacka J, Kruseova J, et al. Serum metallothionein in newly diagnosed patients with childhood solid
tumours. Acta Biochim Pol 2010;57:561-6.
89. Sobol-Milejska G, Mizia-Malarz A, Musiol K, Chudek J, Bozentowicz-Wikarek M, et al. Serum levels of vascular endothelial growth
factor and basic fibroblast growth factor in children with brain tumors. Adv Clin Exp Med 2017;26:571-5.
90. Weathers SP, de Groot J. VEGF manipulation in glioblastoma. Oncology (Williston Park) 2015;29:720-7.
91. Behrends U, Schneider I, Rössler S, Frauenknecht H, Golbeck A, et al. Novel tumor antigens identified by autologous antibody screening
of childhood medulloblastoma cDNA libraries. Int J Cancer 2003;106:244-51.
92. Verly IR, van Kuilenburg AB, Abeling NG, Goorden SM, Fiocco M, et al. Catecholamines profiles at diagnosis: increased diagnostic
sensitivity and correlation with biological and clinical features in neuroblastoma patients. Eur J Cancer 2017;72:235-43.
93. Pricola Fehnel K, Duggins-Warf M, Zurakowski D, McKee-Proctor M, Majumder R, et al. Using urinary bFGF and TIMP3 levels to
predict the presence of juvenile pilocytic astrocytoma and establish a distinct biomarker signature. J Neurosurg Pediatr 2016;18:396-407.
94. Smith ER, Zurakowski D, Saad A, Scott RM, Moses MA. Urinary biomarkers predict brain tumor presence and response to therapy. Clin
Cancer Res 2008;14:2378-86.
95. Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, et al. CBTRUS statistical report: primary brain and other central nervous
system tumors diagnosed in the United States in 2011-2015. Neuro Oncol 2018;20:iv1-iv86.
96. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, et al. Detection of circulating tumor DNA in early- and late-stage human
malignancies. Sci Transl Med 2014;6:224ra24.
97. Pages M, Rotem D, Gydush G, Reed S, Rhoades J, et al. Liquid biopsy detection of genomic alterations in pediatric brain tumors from
cell free DNA in peripheral blood, CSF, and urine. Neuro-Oncology 2018;20:vi142-3.
98. Spreafico F, Bongarzone I, Pizzamiglio S, Magni R, Taverna E, et al. Proteomic analysis of cerebrospinal fluid from children with central
nervous system tumors identifies candidate proteins relating to tumor metastatic spread. Oncotarget 2017;8:46177-90.
99. Cengiz P, Zemlan F, Eickhoff JC, Ellenbogen R, Zimmerman JJ. Increased cerebrospinal fluid cleaved tau protein (C-tau) levels suggest
axonal damage in pediatric patients with brain tumors. Childs Nerv Syst 2015;31:1313-9.
100. Murray MJ, Bell E, Raby KL, Rijlaarsdam MA, Gillis AJ, et al. A pipeline to quantify serum and cerebrospinal fluid microRNAs for
diagnosis and detection of relapse in paediatric malignant germ-cell tumours. Br J Cancer 2016;114:151-62.
101. Banfield E, Brown AL, Peckham EC, Rednam SP, Murray J, et al. Exploratory analysis of ERCC2 DNA methylation in survival among
pediatric medulloblastoma patients. Cancer Epidemiol 2016;44:161-6.
102. Akino T, Han X, Nakayama H, McNeish B, Zurakowski D, et al. Netrin-1 promotes medulloblastoma cell invasiveness and angiogenesis,
and demonstrates elevated expression in tumor tissue and urine of patients with pediatric medulloblastoma. Cancer Res 2014;74:3716-26.